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ABSTRACT
Mammalian tissues display a remarkable com-
plexity of splicing patterns. Nevertheless, only few
examples of tissue-specific splicing regulators are
known. Herein, we characterize a novel splicing
regulator named RBM11, which contains an RNA
Recognition Motif (RRM) at the amino terminus
and a region lacking known homology at the
carboxyl terminus. RBM11 is selectively expressed
in brain, cerebellum and testis, and to a lower extent
in kidney. RBM11 mRNA levels fluctuate in a devel-
opmentally regulated manner, peaking perinatally
in brain and cerebellum, and at puberty in testis,
in concomitance with differentiation events
occurring in neurons and germ cells. Deletion
analysis indicated that the RRM of RBM11 is
required for RNA binding, whereas the carboxyl
terminal region permits nuclear localization and
homodimerization. RBM11 is localized in the nu-
cleoplasm and enriched in SRSF2-containing
splicing speckles. Transcription inhibition/release
experiments and exposure of cells to stress
revealed a dynamic movement of RBM11 between
nucleoplasm and speckles, suggesting that its lo-
calization is affected by the transcriptional status
of the cell. Splicing assays revealed a role for
RBM11 in the modulation of alternative splicing.
In particular, RBM11 affected the choice of alterna-
tive 50 splice sites in BCL-X by binding to specific
sequences in exon 2 and antagonizing the SR
protein SRSF1. Thus, our findings identify
RBM11 as a novel tissue-specific splicing factor
with potential implication in the regulation of alter-
native splicing during neuron and germ cell
differentiation.
INTRODUCTION
The multi-exon nature of genes greatly expands the coding
potential of eukaryotic genomes, by allowing production
of multiple mRNA variants from each gene through dif-
ferential assortment of exons (1,2). This process, known as
alternative splicing (AS), is operated by the spliceosome,
and modulated by the interaction between trans-acting
factors and cis-regulatory sequences within the regulated
exons and/or the ﬂanking introns (3). The best charac-
terized trans-acting factors are the heterogeneous nuclear
ribonucleoproteins (hnRNPs) and the serine–arginine
rich (SR) RNA-binding protein (RBP) families, which
typically act antagonistically to regulate exon recognition
(3–5).
Tissues and organs display remarkable differences
in terms of AS frequency and speciﬁcity (1,2,6). This
tissue-speciﬁc repertoire of splicing variants can be
achieved, at least in part, through modulation of the ex-
pression of ubiquitous trans-acting factors. Indeed, cells
expressing variable amounts of SR proteins or hnRNPs
are expected to differentially regulate a given splicing
event, due to the opposite effects they usually exert on
regulated exons (3–5). Furthermore, these RBPs can
regulate their own expression and that of other splicing
factors in speciﬁc cell contexts. The autoregulation of
hnRNP I, also known as polypyrimidine tract-binding
protein (PTB), provides an excellent example. PTB binds
its own pre-mRNA and triggers the skipping of exon 11,
thus creating a premature termination codon (PTC),
which targets the transcript to the nonsense-mediated
decay pathway (NMD) (7). The SRSF1 gene is also
subject to extensive AS leading to production of six dif-
ferent variants, one being the full-length variant while
the others are retained into the nucleus or targeted to
NMD (8). SRSF1 enhances the production of the
nuclear-retained splice variants, causing its own down-
regulation (8). In addition, Sam68, a ubiquitous splicing
factor, promotes the retention of a cryptic intron in
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the full-length mRNA (9).
Tissue-speciﬁc splicing factors provide an additional
layer of complexity, particularly in organs characterized
by highly differentiated cell types like brain and testis.
For instance, the neuron-speciﬁc NOVA proteins play
an essential role in neurogenesis (10,11), likely due to regu-
lation of AS in genes important for synaptogenesis (10).
Tissue-speciﬁc splicing factors might also cooperate with
ubiquitous proteins to regulate neuron-speciﬁc AS. The
FOX family comprises three members (FOX-1–3) that
are alternatively spliced to yield multiple protein variants
(1,12). FOX-1 and FOX-2 are expressed in brain and
muscle, whereas FOX-3 is restricted to brain. However,
not all neurons express all FOX proteins and splicing of at
least one neuron-speciﬁc exon speciﬁcally correlates only
with FOX-3 expression (12). Notably, FOX-3 strictly
requires the interaction with the PTB-associated splicing
factor (PSF) to regulate this exon (12), thus enrolling a
ubiquitous factor in a neuron-speciﬁc AS event. Splicing
reprogramming in neurons is also regulated by the switch
occurring from PTB to the neuron-speciﬁc nPTB, which
are expressed in a mutually exclusive fashion in developing
brain (7). Gene silencing experiments showed that PTB
and nPTB modulate splicing changes of different sets of
alternative exons during neurogenesis (7), which may
underlie neural cell differentiation.
Germ cell differentiation is another dynamic process
possibly guided by tissue-speciﬁc splicing factors and
characterized by extensive AS (13). Two male germ
cell-speciﬁc members of the RNA-binding motif (RBM)
protein family, RBMY and hnRNPG-T (13), were shown
to regulate testis-speciﬁc exons (14,15). RBMY and
hnRNPG-T interact with two other RBPs highly ex-
pressed in testis, SLM-2 and Sam68 (13). SLM-2 expres-
sion is restricted to neurons and germ cells (16), while
Sam68 is present in most tissues (17) but it is essential
for male fertility (18). Sam68 is expressed in transcription-
ally active male germ cells (18–20), where it promotes AS
(20) and translation of target mRNAs (18).
Given the relatively small number of tissue-speciﬁc
splicing regulators known, it is likely that additional
RBPs are involved in tissue-speciﬁc AS. In the present
work, we have studied the expression and function of
RBM11, a previously uncharacterized RNA Recognition
Motif (RRM) protein. The human gene maps on
Chromosome 21 (21–23), whereas the mouse counterpart
is located on the homologous Chromosome 16. Due to its
genomic localization, which potentially links RBM11 to
the Down syndrome, the gene has been included in expres-
sion studies, which suggested a restricted pattern of ex-
pression (21–23). These reports documented expression
in brain and testis (21), or in brain, testis and spleen (23)
or uniquely in testis (22). Beside these partially divergent
results, no direct studies on either human or mouse
RBM11 have been performed to date. Herein, we
provide evidence that RBM11 is expressed in selected
tissues in a developmentally regulated fashion. RBM11
colocalizes with splicing speckles, binds RNA, and modu-
lates splicing events. These results suggest that RBM11 is
a novel tissue-speciﬁc splicing factor with potential impli-
cation in regulation of AS in brain and testis.
MATERIALS AND METHODS
Plasmid constructs
The human RBM11 cDNA (accession no. NM_144770)
was ampliﬁed by RT–PCR from Hek293T RNA, using
the Finnzyme Phusion DNA Polymerase, and cloned
into the HindIII–BamHI restriction sites of p3XFlag
(Sigma-Aldrich), the XhoI–SalI restriction sites of
pEGFP-C1 (Clontech) and the BamHI–XhoI restriction
sites of pGEX-4T1 (GE Healthcare). The cDNAs
encoding the RRM or RRM portion of RBM11 were
ampliﬁed by PCR using Flag-RBM11 as template and
cloned as above. Mouse Rbm11 cDNA (accession
no. NM_198302) was ampliﬁed from 30 die post partum
(dpp)-old mouse testis RNA, as described above for
human RBM11, and cloned into HindIII–BamHI restric-
tion sites of p3XFlag (Sigma-Aldrich). cDNAs were
sequenced by Cycle Sequencing (BMR Genomics). The
BCL-X (24–26), E1A (27), CD44 (28) and SMN2 (29)
minigenes were previously described. All PCR primers
used are listed in Supplementary Table S1.
Cell cultures, transfections, treatments and in vivo
splicing assay
Germ cells were puriﬁed by elutriation from juvenile
or adult testis as described (19). Hek293T and HeLa
cells were maintained in Dulbecco’s modiﬁed Eagle
Medium (DMEM; Gibco BRL) supplemented with 10%
fetal bovine serum (LONZA), penicillin and streptomycin.
Transfections were performed with 1mg of the indicated
RBM11 constructs, ±0.5mg of the indicated minigene,
using Lipofectamine 2000 (Invitrogen). RNAi transfec-
tions were performed as described (29) with RBM11 and
SRSF1 siRNAs (Supplementary Table S1). Twenty-four
hours after transfection, cells were collected for RNA or
biochemical analyses and processed as described (24).
Total RNA was isolated using cold TRIzol reagent
(Invitrogen) and resuspended in RNase-free water
(Sigma-Aldrich). For confocal analysis, cells were seeded
on cover slips and treated with or without 1mM
mitoxantrone (MTX, Sigma-Aldrich) for 2h, 0.5mM
arsenite for 30min or 50mM cisplatin (Sigma-Aldrich)
for 1h. Cells were then ﬁxed and stained for immunoﬂuor-
escence analysis. For transcription inhibition/release ex-
periments, HeLa cells were incubated for 6h with 75mM
5,6-Dichlorobenzimidazole 1-b-D-ribofuranoside (DRB,
Sigma-Aldrich), rinsed and let recover in fresh medium
for the indicated time.
Immunoﬂuorescence analysis
HeLa cells were ﬁxed and stained for immunoﬂuores-
cence analysis as previously described (28). The primary
antibodies used were: mouse anti-SRSF2 and anti-Flag
(1:500; Sigma-Aldrich), goat anti-TIA-1 (1:200; Santa
Cruz Biotechnology), mouse anti-RNAP II H5 IgM
(1:200; Abcam). The secondary antibodies used
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and cy3-coniugated donkey anti-mouse IgM (1:500;
Jackson Immunoresearch). Confocal analyses were per-
formed using a Leica confocal microscope and a
Plan-Neoﬂuar HCX 40.0 /1.25 oil UV objective and
acquired using IAS AF Lite software (Leica
Microsystems). Images were saved as TIFF ﬁles;
Photoshop (Adobe) was used for composing the panels.
In vitro RNA synthesis, biotin–RNA pull down and
in vitro UV crosslink
Templates for RNA synthesis were generated using PCR
products ampliﬁed with forward primers containing the
T7 promoter sequence upstream of the exon 2 sequence
of either wild-type or mutated BCL-X minigenes. Reverse
primers were complementary to either the sequence in
exon 2 or intron 2. Ampliﬁed bands were gel-puriﬁed
and used as templates (1mg) for in vitro RNA transcrip-
tion with T7 polymerase (MAXIScript kit, Ambion) and
Biotin RNA Labeling Mix (Roche). RNA was puriﬁed by
phenol–chloroform and diluted in RNAse-free water
(Sigma-Aldrich). Biotin–RNA/streptavidin pull-down ex-
periments were performed using nuclear extracts from
Hek293T cells transfected with wild-type or mutant
Flag-RBM11 plasmids. In vitro UV crosslink was per-
formed as described (29) using BCL-X exon 2 RNA
transcribed in vitro from wild X2.13 or B2 plasmids in
the presence of 30mCi GTP and puriﬁed on Sephadex
G50. RNA was incubated for 10min in the presence of
GST or GST-RBM11 (200ng). After RNase treatment,
samples were resolved by 10% SDS–PAGE and
analyzed by autoradiography.
UV crosslink RNA–protein immunoprecipitation (CLIP)
Hek293T cells transfected with Flag-RBM11 alone or with
BCL-X minigene plasmids were washed with PBS and
UV-irradiated (400mJ). Cells were collected in lysis
buffer: 50mM Tris pH 8, 100mM NaCl, 1% NP40,
1mM MgCl2, 0.1mM CaCl2, 0.5mM NaVO4,1 m M
dithiothreitol, protease inhibitor cocktail, RNase inhibitor
(New England Biolabs) and incubated 10min on ice.
Extracts were then incubated with RNase-free DNase
(10units/100mg) for 30min at 37 C, and centrifuged at
15000g for 10min at 4 C. An amount of 50mgo f
extract (RNA input) was treated with Proteinase K
(50mg) for 30min at 37 C before RNA puriﬁcation.
The rest of the extract was pre-cleared for 1h on protein
A–Sepharose beads and for 1h on protein A/G-Sepharose
beads with rabbit IgG (2mg/mg of extract), 0.25mg/ml
tRNA and 0.01% BSA. Extracts were then incubated as
for the second pre-clearing but in the presence of 1mg
mouse anti-Flag IgGs for 2h at 4 C. After three washes
at room temperature in lysis buffer supplemented with
1M NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1%
SDS and 1mM EDTA, and two washes in lysis buffer,
beads were resuspended in 100ml of lysis buffer. An
aliquot (10%) was kept for western blot analysis and the
rest incubated with 50mg Proteinase K at 37 C for 20min.
RNA was isolated by standard procedures and used for
real time PCR analyses.
RT–PCR and real-time PCR analyses
Total RNA (0.2–1mg) from transfected cells or tissues was
used for RT–PCR using M–MLV reverse transcriptase
(Invitrogen). A total of 5% of the RT reaction was used
as template and PCR products were analyzed by ethidium
bromide agarose gel. Quantitative real-time PCR (qPCR)
was performed using LightCycler 480 SYBR Green I
Master and the LightCycler 480 System (Roche),
according to manufacturer’s instructions. For crosslink
immunoprecipitation (CLIP) analyses, each sample was
normalized with respect to its input. BCL-X RNA
associated with RBM11 is represented as fold enrichment
relative to samples transfected with empty vectors.
All primers used are listed in the Supplementary Table S1.
RESULTS
RBM11 is expressed in a cell- and tissue-speciﬁc
pattern in mouse and human
RBM11 expression was analyzed in a panel of cell lines
derived from various human tissues by RT–PCR.
Screening with primers that amplify the whole open
reading frame (a–c in Figure 1A) showed high expression
levels only in Hek293T kidney cells and Panc-1 pancreatic
adenocarcinoma cells, while weak expression was
observed in NT2D1 testicular embryonic carcinoma cells
(Figure 1A). By using an internal set of primers that
amplify a smaller fragment (a–b in Figure 1A) or quanti-
tative real-time PCR (qPCR) (Supplementary Figure S1A
and B), a faint signal was also detected in SH-5YSY
neuroblastoma cells but not in HeLa cells. These results
conﬁrmed a restricted pattern of expression for human
RBM11 (21–23).
Analysis of expression of the highly homologous mouse
gene in tissues obtained from 30 dpp mice showed high
levels only in brain, cerebellum and testis, which yielded
the strongest signal, whereas barely detectable levels were
observed in kidney (Figure 1B). Quantitative analysis by
qPCR yielded similar results (Supplementary Figure S1C),
thus indicating that RBM11 displays a restricted pattern
of expression also in the mouse. To investigate whether
Rbm11 mRNA expression varies during development,
we selected the organs expressing high levels of the gene.
RT–PCR analyses starting from Day 10.5 of embryonic
development (E10.5) until adulthood showed that Rbm11
expression increased during the fetal life in brain (Figure
1C) and cerebellum (Figure 1D), reaching a peak peri-
natally (P0-3dpp). At this time dendrite maturation and
synaptic connections are reﬁned (30,31), suggesting a cor-
relation between Rbm11 expression and cell differentiation
events. Indeed, we also found that its expression could be
induced by triggering differentiation of both mouse
(NSC34; Figure 1E) and human (SH-5YSY; Supple-
mentary Figure S1D) neuronal cell lines in culture.
In testis, Rbm11 expression increased rapidly from 3 to
16 dpp (Figure 1F), concomitantly with the onset of
germ cell meiotic differentiation (32), and then remained
high at least until 60 dpp, when testis is largely populated
by post-meiotic spermatids (32). This trend was conﬁrmed
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Rbm11 expression in mitotic spermatogonia and high ex-
pression in meiotic spermatocytes and post-meiotic sperm-
atids (Figure 1G). Collectively, these observations suggest
that Rbm11 is expressed in a tissue-speciﬁc manner and
displays maximal levels in concomitance with cell differ-
entiation events in brain, cerebellum and testis.
RBM11 protein binds RNA and homodimerizes
Human and murine RBM11 protein sequences show a
high degree of homology, with 67% identity and 74%
similarity (Figure 2A and B). The main difference is rep-
resented by the lack of a stretch of residues within the
carboxyl terminal region in murine RBM11, whereas the
predicted RRM presents only two conservative substitu-
tions (Figure 2A). Due to the presence of an RRM,
RBM11 is annotated as a putative RBP. The RRM is
one of the most abundant protein domains in eukaryotes,
which characterizes RBPs involved in all steps of RNA
processing (33). However, although most RRMs bind
RNA, some of these domains are exclusively involved
in protein–protein interactions (33). To test whether
RBM11 can bind RNA in vitro, we performed pull-
down assays with synthetic, homopolimeric RNA.
Human Flag-RBM11 expressed in Hek293T cells efﬁ-
ciently bound RNA, with marked selectivity for polyU
RNA (Figure 2C). In contrast, two other RBPs, the
polyA-binding protein 1 (PABP1) and Sam68, bound
with similar efﬁciency to both polyU and polyA RNAs
(Figure 2C). Strong binding to polyU RNA was also
observed for murine RBM11 (mRBM11 in Figure 2B
and D). Deletion of the RRM (RRM) in human
RBM11 completely abolished binding to polyU RNA,
whereas the isolated RRM could still bind, albeit with
reduced efﬁciency (Figure 2B and D).
Several RRM-containing proteins homodimerize, and
in some cases this is required for RNA-binding efﬁciency
(33). To test whether RBM11 homodimerizes, Hek293T
cells were cotransfected with Flag- and GFP-tagged
full-length or mutant RBM11 (Figure 2B). We observed
that GFP-RBM11 was efﬁciently coimmuno-
precipitated with Flag-RBM11. Deletion of the RRM in
GFP-RBM11(RRM) did not impair this interaction,
whereas GFP-RBM11(RRM) was unable to associate
Figure 1. RBM11 is expressed in a cell- and tissue-speciﬁc pattern in mouse and human. (A and B) Schematic representation of human RBM11 and
mouse Rbm11, with the position of the PCR primers used. (A) RT–PCR analysis (35 cycles) of RBM11 expression in the indicated human cell lines.
GAPDH was used as internal standard. (B–D, F and G) RT–PCR analysis of Rbm11 expression in the mouse. Total RNA (1mg) from 30 dpp mouse
tissues (B), fetal and post-natal brain (C) and cerebellum (D), post-natal testis (F) and puriﬁed germ cells (G) were collected at the indicated ages or
stages of differentiation was used for RT–PCR analyses of Rbm11 expression (28 cycles). Gapdh was used as an internal standard. (E) Conventional
(left panels) and qPCR of Rbm11 expression in the mouse neuronal cell line NSC34 under basal conditions and after neuronal differentiation induced
by retinoic acid and glial derived neurotrophic factor (RA+GDNF). Induction of Pax6 was analyzed as marker of neuronal differentiation.
1024 Nucleic Acids Research, 2012,Vol.40, No. 3with Flag-RBM11 (Figure 2E). These experiments suggest
that RBM11 requires the RRM for RNA binding and the
C-terminal region for homodimerization.
RBM11 colocalizes with splicing speckles in the nucleus
Alignment of the RRM of human RBM11 revealed
highest homology with that of proteins involved in pre-
mRNA splicing (RBM7, SF3B4, RBMY and hnRNP M),
cleavage and polyadenylation (CSTF2), and mRNA
translation (RBM3) (Supplementary Figure S2A). To
gain insight into the function of RBM11, we analysed
its subcellular localization in HeLa cells. GFP-RBM11
and GFP-RBM11(RRM) were exclusively localized in
the nucleus, whereas GFP-RBM11(RRM) was equally
distributed throughout the cell (Supplementary Figure
S2B). In line with this result, analysis of the primary
sequence revealed the presence of lysine/arginine-rich po-
tential nuclear localization signals (NLS) in the carboxyl
terminus of human and mouse RBM11 (Figure 2A).
Confocal analysis showed an enrichment of GFP-
RBM11 (Figure 3A) and Flag-RBM11 (Supplementary
Figure S2C) in granular structures within the nucleo-
plasm. Costaining with the SR protein SRSF2 (SC35)
(Figure 3A) or the U2AF65 splicing factor (Supple-
mentary Figure S2D) suggested that these structures are
splicing speckles. Nonetheless, depletion of RBM11 by
RNAi, like depletion of SRSF1, did not affect speckle
assembly (Supplementary Figure S2E), indicating that it
is not an essential structural component. GFP-RBM11
(RRM) localized in the nucleus but did not accumulate
in SRSF2 speckles (Figure 3A), nor did the nuclear pool
of GFP-RBM11(RRM), which showed a diffused distri-
bution (Figure 3A). These results suggest that the
full-length protein is required for association with
splicing speckles and that RBM11 might be implicated
in splicing regulation.
Analyses of nascent chromatin-associated RNAs have
indicated that splicing of most exons occurs cotranscrip-
tionally (34,35). In line with this notion, inhibition of
Figure 2. RBM11 binds synthetic homopolymeric RNA and homodimerizes. (A) Alignment of the human (black) and mouse (red) RBM11 protein
sequences. Conserved residues are highlighted in gray; dashed line represents sequences absent in mouse RBM11. The percentage of identity and
similarity is reported. The boxed sequence represents the RRM, putative nuclear localization signals are underlined. (B) Schematic representation of
RBM11 full length and deletion mutants used in the study. (C, D) Extracts from Hek293T cells transfected with either Flag-RBM11 (C) or with
human Flag-RBM11 (hRBM11), Flag-RBM11(RRM), Flag-RBM11(RRM) and mouse Flag-RBM11 (mRBM11) (D), were incubated with polyA-
or polyU-RNA sepharose beads. Bound proteins were analyzed by western blot with anti-Flag, anti Sam68 or anti-PABP1 antibodies. (E) Nuclear
extracts from Hek293T cells transfected with the indicated plasmids were incubated with ANTI-FLAG M2 Afﬁnity Agarose Gel beads and bound
complexes were analyzed by western Blot with anti-Flag or anti-GFP antibodies.
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including SRSF2, in nuclear speckles (36). To investigate
whether RBM11 localization was affected by transcrip-
tion, we transiently inhibited transcription in HeLa cells.
Incubation with the transcription inhibitor DRB sup-
pressed serine 2 phosphorylation of the RNA polymerase
II (RNAPII) (H5 staining in Figure 3B) and inhibited
transcription, as monitored by bromo-uridine (BrU)
incorporation (Supplementary Figure S3A). Under these
conditions, RBM11 accumulated in nuclear speckles
(Figure 3B). Release of the cells from DRB inhibition
caused a sharp increase in RNAPII phosphorylation and
redistribution of RBM11 from the speckles to the nucleo-
plasm. A tight correlation was observed between serine 2
phosphorylation, which marks the RNAPII involved in
transcript elongation (37), and diffused localization
Figure 3. Subcellular localization of RBM11. (A) Subcellular localization analysis of wild-type and mutant RBM11 protein. HeLa cells were
transfected with the indicated constructs and analyzed by confocal microscopy. Green signal shows GFP ﬂuorescence and red signal shows
SFRS2 staining. The full-length RBM11 accumulates in nuclear granules that partially colocalize with SFRS2 (arrows in the merge panels). (B)
Confocal microscopy analysis of HeLa cells transfected with GFP-RBM11 and treated for 6h with DRB (top panels), before release for 1, 2 or 5h.
Cells were stained with the H5 RNAPII antibody, which speciﬁcally detects the phosphorylated serine2 protein. GFP signal is in green. White arrows
indicate accumulation of RBM11 in speckles in cells treated with DRB. (C, D) HeLa cells were transfected with the GFP-RBM11 plasmid and
treated without (Ctrl) or with 1mM MTX (2h) or 0.5mM Arsenite (30min). Cells were stained with antibodies for SFRS2 (C) or TIA-1 (D) and
analyzed by confocal microscopy. The merge panels show the colocalization between RBM11 and SC35 or TIA-1 upon stress in nuclear granules
(arrows). Arrowheads indicate localization of TIA-1 in cytoplasmic stress granules. Scale bar=10mm.
1026 Nucleic Acids Research, 2012,Vol.40, No. 3of RBM11 in the nucleoplasm. Both processes peaked at
1–2h after DRB release and were partially attenuated by
5h, when RBM11 started to accumulate again in nuclear
speckles (Figure 3B). These observations suggest that,
similarly to other splicing regulators, RBM11 is cotran-
scriptionally recruited to nascent pre-mRNAs.
The localization of RBM11 is inﬂuenced by genotoxic
and oxidative stresses
Gene transcription is modulated at various steps by RBPs
during the cellular response to stress (38,39). To investi-
gate whether the localization of RBM11 is affected by
stress, we treated HeLa cells with the DNA topoisomerase
II inhibitor mitoxantrone (MTX) (Figure 3C and D) or
the alkylating agent cisplatin (Supplementary Figure S3B).
Both genotoxic drugs caused accumulation of GFP-
RBM11 in nuclear speckles, together with SRSF2
(Figure 3C and Supplementary Figure S3B) and the
stress–response RBP TIA-1 (Figure 3D). A similar
relocalization was observed after treatment with arsenite
to induce oxidative stress (Figure 3C and D). This accu-
mulation of RBPs in nuclear stress granules may reﬂect a
redistribution of transcriptionally active foci within the
nucleus in response to genotoxic and oxidative stress
(28,38). Notably, while TIA-1 relocalized also in cytoplas-
mic stress granules after oxidative stress, RBM11, like
SRSF2, remained exclusively in the nucleus of cells
treated with arsenite (Figure 3D). The relocalization of
RBM11 after stress was not a general response of all
RBPs, as hnRNP A1 did not accumulate in nuclear
granules in these cells (Supplementary Figure S3C).
RBM11 is a novel splicing regulator
The presence of an RRM domain is a common feature
of splicing factors of the hnRNP and SR protein
families (3–5). Given its nuclear localization and associ-
ation with splicing speckles, we asked if RBM11 displays
splicing activity. To address this issue, we performed
in vivo splicing assays using the E1A minigene, a
commonly used splicing target that contains several 50
and 30 alternative splice sites (27) (Figure 4A). RBM11
expression caused a dose-dependent effect on E1A
splicing in HeLa cells. In particular, we observed a
decrease in the usage of the proximal 50 splice sites (13S
and 12S variants) and a concomitant increase in the choice
of the distal 50 splice site (9S) and of the unspliced
pre-mRNA (Figure 4B). In contrast, no change in expres-
sion of the 30 alternatively spliced variants 11S and 10S
was observed (Figure 4B). Importantly, RBM11(RRM)
and RBM11(RRM) only weakly affected E1A splicing
(Supplementary Figure S4A), suggesting that the RRM is
required but not sufﬁcient to promote the selection of the
distal 50 splice site in E1A. To further test the splicing
activity of RBM11, we used minigenes that recapitulate
alternative 50 splice site choice (BCL-X), variant exon in-
clusion (CD44) or exon skipping (SMN2). RBM11
strongly enhanced splicing of BCL-XS in Hek293T
(Figure 4C) and HeLa cells (Supplementary Figure S4B
and C), whereas it exerted negligible effects on CD44 and
SMN2 splicing.
RBM11 modulates BCL-X splicing in a sequence
speciﬁc manner
We further investigated the effect of RBM11 on BCL-X,
which represents a functionally relevant splicing event.
The BCL-X gene encodes two splice variants, through
the choice of alternative 50 splice sites in exon 2. The
long variant, named BCL-XL, displays anti-apoptotic
properties, whereas the short BCL-XS variant promotes
apoptosis (24). Thus, modulation of BCL-X splicing
affects cell survival. We observed that, like for E1A, the
BCL-X splicing activity of RBM11 deletion mutants was
compromised (Figure 4D). To test whether RBM11 can
directly modulate this splicing event, we performed
a pull-down assay using biotinylated exon 2 RNA.
RBM11 efﬁciently bound to BCL-X RNA, whereas
neither RBM11(RRM) nor the RRM alone interacted
(Figure 4E), suggesting that the full-length protein was
required for both RNA binding and splicing.
Importantly, interaction of RBM11 with BCL-X RNA
also occurred in vivo, as indicated by enrichment of en-
dogenous BCL-X mRNA in UV CLIP assays of
Flag-RBM11 in Hek293T cells (Figure 4F).
We next asked if speciﬁc sequences in BCL-X were
required for the effect of RBM11 on splicing. Sequential
deletions of the BCL-X minigene showed that RBM11 still
exerted an effect when exon 1 and the ﬁrst half of exon 2
were eliminated (Figure 5A). Thus, we used a set of
plasmids containing internal exon 2 deletions (25,26)
(Figure 5B). Deletions upstream of the BCL-XS 50 splice
site affected splicing of the minigene, either by reducing or
increasing the Xs/XL ratio, but did not abolish the effect
of RBM11 (Figure 5C). In contrast, the B2 deletion
downstream of the BCL-XS 50 splice site completely abol-
ished the ability of RBM11 to induce BCL-XS splicing
(Figure 5C), whereas deletion of a shorter sequence in
the B2G plasmid did not. These results suggest that
RBM11 affects BCL-X splicing by directly binding to a
sequence downstream of the distal 50 splice site (Figure 5B
and C). Indeed, in vitro UV crosslink experiments showed
that GST-RBM11 was crosslinked to wild-type exon 2
RNA (X2.13), whereas binding was almost abolished
when the B2 sequence was deleted (Figure 5D).
Furthermore, CLIP experiments in Hek293T cells con-
ﬁrmed that RBM11 was efﬁciently crosslinked in vivo to
wild-type BCL-X mRNA, but not to the B2 deletion
mutant (Figure 5E). These experiments suggest that
RBM11 directly interacts with its splicing target.
RBM11 antagonizes SRSF1 in the modulation of
BCL-X splicing
Splicing of the anti-apoptotic BCL-XL variant is
promoted by SRSF1 (24). To test whether RBM11 nega-
tively affected SRSF1 activity, we performed a pull-down
experiment with nuclear extracts of mock- or
RBM11-transfected Hek293T cells. SRSF1 efﬁciently
bound exon 2 RNA when nuclear extracts from
mock-transfected cells were used (Figure 6A). However,
this interaction was strongly decreased when RBM11 was
upregulated and bound to exon 2 RNA. Competition with
SRSF1 binding appeared speciﬁc, as expression of
Nucleic Acids Research,2012, Vol.40, No. 3 1027RBM11 did not affect binding of other regulators of
BCL-XS splicing like Sam68 and hnRNP F/H (24,25)
(Figure 6A).
Next, we tested whether RBM11 competes with SRSF1
for BCL-X splicing also in live cells. As expected,
up-regulation of SRSF1 enhanced splicing of BCL-XL in
Hek293T cells (Figure 6B). Importantly, coexpression
of increasing amounts of RBM11 reverted this effect
(Figure 6B). In contrast, the RBM11 deletion mutants
that are defective in splicing activity and exon 2 binding
did not efﬁciently counteract SRSF1 activity (Supple-
mentary Figure S5). These results suggest that RBM11
promotes splicing of BCL-XS by competing with recruit-
ment of SRSF1 to exon 2.
DISCUSSION
Our work characterizes the RRM-containing protein
RBM11 as a novel tissue-speciﬁc splicing factor. RBM11
is selectively expressed in few human cell lines, an evidence
Figure 4. RBM11 regulates AS. (A) Schematic representation of the E1A-derived splicing variants. (B) RT–PCR analysis of E1A splicing in HeLa
cells transfected with either empty vector or with increasing amount of Flag-RBM11. Splicing products are indicated on the right of the panel. The
bar graph below the PCR panel shows the quantiﬁcation of the major E1A mRNA variants: light gray bars, dark gray bars, and black bars represent
9S, 12S and 13S variants, respectively. Quantiﬁcation of the 11S and 10S mRNA isoforms, which showed no change in the splicing assays, was
omitted in the graph. Data represent mean±SD of three experiments. Western blot analysis of RBM11 expression and tubulin as loading control
are shown above the PCR panel. (C) RT–PCR analysis of splicing assay in Hek293T cells cotransfected with either empty vector or Flag-RBM11
and the indicated minigene. The ratio of the splicing variants (mean±SD of three experiments) is shown below each image. (D) RT–PCR analysis of
the splicing assays in HEK293T cells cotransfected with the indicated plasmids and the BCL-X minigene. The bar graph represents the BCL–XS/XL
ratio (mean±SD of three experiments). Western blot analysis of wild-type and mutant RBM11 expression is shown above the PCR panel. (E)
Western blot analysis of the biotin–RNA pull-down experiment with BCL-X exon-2 RNA and extracts of cells expressing wild-type or mutant
Flag-RBM11. Empty streptavidin beads were used as control (right panel). The left panel shows the western blot analysis of the extracts used for the
pull-down experiment. (F) UV RNA/protein CLIP of Flag-RBM11. Associated BCL-X RNA was quantiﬁed by qRT–PCR. Bar graph (left panel)
shows fold enrichment relative to the sample transfected with empty vector. Right panels show western blot analysis of the immunoprecipitated
proteins.
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human tissues (21–23). Expression of the mouse Rbm11
gene is also restricted to few tissues, where it is regulated in
a developmental manner. In brain and cerebellum, its
levels increased during embryogenesis (E10.5–15.5),
when neurogenesis and neural cell migration occur, and
peaked perinatally (P0–3 dpp), when the vast array of cell
types composing the nervous system appears and the
mature cytoarchitecture of these organs takes shape
(30,31). In the testis, Rbm11 expression levels increased
rapidly from 3 to 16 dpp, when mitotic spermatogonia
differentiate into meiotic spermatocytes (32). Thus,
Rbm11 expression seems to correlate with developmental
stages when important cell differentiation events occur,
suggesting that it might play a role in the differentiation
program of germ cells and neuronal subtypes. Brain and
testis have been annotated as the tissues expressing the
highest levels of splicing factors and AS events (6,40,41),
which could contribute to the generation of proteomic
diversity in highly specialized cells, like neurons and
germ cells. Nevertheless, only a limited number of brain-
and testis-speciﬁc splicing factors have been described so
far (1,10–16), raising the possibility that additional,
uncharacterized RBPs participate to regulation of
splicing in these tissues. Although the lack of valid
antibodies to conﬁrm RBM11 protein expression may
limit the interpretation of our results, the apparently
speciﬁc expression of RBM11 in brain, cerebellum and
testis reinforces the notion that neurons and germ cells
express a unique repertoire of splicing factors.
Figure 5. RBM11 binds BCL-X RNA and affects its AS in a sequence-dependent manner. (A) RT–PCR analysis of the in vivo splicing assays in
Hek293T cells transfected with Flag-RBM11 and the wild-type BCL-X minigene (top panel) or its 50-deletion derivatives illustrated on the left side
(middle and bottom panel). Bar graphs show the ratio of BCL-XS/XL and represent the mean±SD of three experiments. (B) Schematic represen-
tation of the X2.13 minigene and its mutants. (C) RT–PCR analysis of the in vivo splicing assay. In Hek293T cells cotransfected with either
Flag-RBM11 or empty vector as control and the indicated minigene. The bar graph below the PCR panel represents the ratio of BCL–XS/XL
(mean±SD of three experiments). (D) UV-crosslink experiment was performed by incubating
32P-labeled BCL-X exon 2 RNA derived from the
indicated minigene with GST or GST-RBM11. The reaction mixtures were UV-irradiated and cross-linked proteins were analyzed by SDS–PAGE
and autoradiography. Coomassie staining of the puriﬁed proteins used for the experiment is shown on the left. (E) CLIP assay of Flag-RBM11 in
Hek293T cells transfected with wild-type (X2.13) or mutated (B2) BCL-X minigenes. Associated BCL-X RNA in the anti-Flag immunoprecipitates
was quantiﬁed by qRT–PCR (Figure 4). Western blot analysis of the immunoprecipitated proteins is shown on the right.
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presence of a single RRM at the amino terminus.
Beside the presence of NLS sequences at the C-terminus,
no other known functional domains were identiﬁed in the
remaining two-thirds of the protein. The RRM is one of
the most abundant protein domains in eukaryotes, and
characterizes RBPs involved in multiple aspects of RNA
metabolism (33). Nevertheless, not all RRMs can directly
bind RNA. In some cases, as for the exon junction protein
Y14, the RRM is involved in protein–protein interactions
(33). In proteins containing multiple RRMs, like hnRNP
A1, portions of one RRM can contact another RRM,
thereby promoting cooperative binding to RNA (33).
Since no information on the functional role of RBM11
was available, it was relevant to investigate the biochem-
ical properties of the protein. We found that RBM11
binds RNA and that this interaction requires its RRM.
However, although the RRM was sufﬁcient to bind RNA,
its interaction with homopolymeric polyU or with BCL-X
exon 2 RNA was much weaker than that of full-length
RBM11. As multiple RRMs can allow higher afﬁnity or
cooperative binding to RNA (33), one possibility is that
RBM11 needs to dimerize or to interact with other
proteins to bind RNA with high afﬁnity. Our experiments
indicate that RBM11 homodimerizes in live cells, and that
the C-terminal region downstream of the RRM is neces-
sary for this interaction. Thus, we propose that RBM11
requires the RRM for the interaction with RNA and the
C-terminal region for homodimerization.
RRM-containing proteins have been involved in basic-
ally all the steps of RNA processing and metabolism, from
cotranscriptional splicing to RNA decay (33). Several ob-
servations point to a role of RBM11 in the regulation of
splicing. Live imaging and confocal microscopy indicated
that RBM11 is exclusively localized in the nucleus.
The protein is enriched in nuclear granules that are
costained with antibodies for SRSF2, suggesting that
these structures are splicing speckles. Furthermore, simi-
larly to other splicing regulators, RBM11 localization is
dynamically modulated in response to an altered tran-
scriptional status of the cell. For instance, inhibition of
transcription caused accumulation of RBM11 in the
nuclear speckles, as observed for SRSF2 and other
splicing factors (36). However, upon release from the
DRB block, RBM11 rapidly diffused in the nucleoplasm
concomitantly with increased serine 2 phosphorylation of
RNAPII, which marks the transcriptional elongation
phase (37). This redistribution suggests recruitment of
RBM11 to nascent transcripts in the nucleoplasm and its
involvement in cotranscriptional RNA processing events.
Notably, RNAPII accumulates in splicing speckles upon
transcription inhibition as well (36). Moreover, transcrip-
tionally active (BrU positive) foci that form after exposure
of cells to genotoxic stress also accumulate serine
2-phosphorylated RNAPII and splicing factors (28).
RBM11 behaves in the same manner and colocalize with
SRSF2 and TIA-1 in these nuclear foci after genotoxic
and oxidative stress, but not in TIA-1-containing cyto-
plasmic stress granules, suggesting that its function is re-
stricted to the nucleus. Thus, we propose that RBM11 is
mainly involved in cotranscriptional RNA processing
events together with other splicing factors.
Our study shows that RBM11 can modulate AS events.
By using a panel of previously characterized minigenes, we
found that it selectively affects splicing of E1A and
BCL-X, but not that of CD44 and SMN2. This selectivity
might indicate a sequence-speciﬁc role of RBM11 in
splicing. Other observations support this hypothesis.
First, we found that, unlike Sam68 and the RRM-
containing protein PABP1, RBM11 displays high
Figure 6. RBM11 antagonizes SRSF1-mediated BCL-X splicing. (A) Western blot analysis of the RNA pull-down experiment performed using
biotinylated BCL-X exon-2 RNA and extracts of control or Flag-RBM11 expressing Hek293T cells. Empty streptavidin beads were used as control
(right panel). (B) RT–PCR analysis of the in vivo splicing assays of the BCL-X minigene in Hek293T cells transfected with Flag-SRSF1 and
increasing amounts of Flag-RBM11, either alone or in combination, as described (top panel). Bar graph shows the BCL–XS/XL ratio and represents
the mean±SD of three experiments. Western blot analysis of RBM11, SRSF1 and tubulin as loading control is shown above the PCR panel.
1030 Nucleic Acids Research, 2012,Vol.40, No. 3selectivity for polyU homopolymeric RNA in vitro.
Moreover, crosslink experiments in vitro and in live cells
showed that RBM11 directly binds BCL-X RNA.
Up-regulation of RBM11 strongly induced the BCL-XS
variant. However, neither the RRM alone nor
RBM11(RRM) could recapitulate the effect of the
full-length protein. Since neither deletion mutant efﬁcient-
ly bound BCL-X exon 2, these results suggest that RBM11
directly modulates splicing events by interacting with
target sequences in the pre-mRNA. In support of this hy-
pothesis, deletion of 78bp located between the two alter-
native 50 splice sites in exon 2 strongly reduced crosslink of
RBM11 to the BCL-X RNA and suppressed its effect on
splicing. Importantly, binding of RBM11 to BCL-X exon
2 RNA impaired recruitment of SRSF1 and competed
with its ability to enhance BCL-XL splicing, suggesting
that RBM11 might antagonize SR proteins like an
hnRNP.
Our study has not addressed the physiological role of
RBM11. However, its highly restricted pattern of expres-
sion allows some speculations. We found that RBM11
expression increases at developmental stages when major
differentiation events occur in brain and testis (30–32).
Furthermore, in the testis RBM11 is strongly expressed
in post-mitotic spermatocytes and spermatids, and to a
lower extent in mitotic spermatogonia. Thus, it is conceiv-
able that RBM11 participates to changes in gene expres-
sion required to insure correct differentiation of neurons
and germ cells. In this regard, it is noteworthy that its
putative target BCL-X is an essential gene for the devel-
opment of the nervous system, where its ablation leads to
massive cell death in post-mitotic neurons but not in
neural progenitor cells (42). It will be interesting to inves-
tigate whether changes in the expression levels of RBM11
affect development of the nervous system, as many
neurodegenerative diseases seem to depend on aberrant
AS and/or splicing factors expression (43). RBM11 is
among the genes putatively linked to Down syndrome
(21–23), and it will also be interesting to test whether its
unbalanced expression in patients with chromosome 21
trisomy can lead to changes in the splicing pattern of
genes that affect the pathology.
In conclusion, our study describes the characterization
of a novel tissue-speciﬁc splicing factor that might be
required for the proper developmental program of
neurons and germ cells.
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